<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A1526</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 1526 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  GERRY SCHARFENBERGER</p>

<p class=bpuSponsor>District 13 (Monmouth)</p>

<p class=bpuSponsor>Assemblywoman  VICTORIA A. FLYNN</p>

<p class=bpuSponsor>District 13 (Monmouth)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Classifies xylazine as Schedule III controlled
dangerous substance under certain circumstances.</p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning xylazine and amending P.L.1970, c.226.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    Section 7 of P.L.1970, c.226
(C.24:21-7) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     7.    Schedule III.</p>

<p class=MsoNormal style='line-height:150%'>     a.     Tests. The director
shall place a substance in Schedule III if he finds that the substance: (1) has
a potential for abuse less than the substances listed in Schedules I and II;
(2) has currently accepted medical use in treatment in the United States; and
(3) abuse may lead to moderate or low physical dependence or high psychological
dependence.</p>

<p class=MsoNormal style='line-height:150%'>     b.    The controlled dangerous
substances listed in this section are included in Schedule III, subject to any
revision and republishing by the director pursuant to subsection d. of section
3 of P.L.1970, c.226 (C.24:21-3), and except to the extent provided in any
other schedule.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Any material, compound,
mixture, or preparation which contains any quantity of the following substances
associated with a stimulant effect on the central nervous system:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   Amphetamine, its salts,
optical isomers, and salts of its optical isomers.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   Phenmetrazine and its
salts.</p>

<p class=MsoNormal style='line-height:150%'>     (3)   Any substance which
contains any quantity of methamphetamine, including its salts, isomers, and
salts of isomers.</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Methylphenidate.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Any material, compound,
mixture, or preparation which contains any quantity of the following substances
having a potential for abuse associated with a depressant effect on the central
nervous system:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   Any substance which
contains any quantity of a derivative of barbituric acid, or any salt of a
derivative of barbituric acid, except those substances which are specifically
listed in other schedules</p>

<p class=MsoNormal style='line-height:150%'>     (2)   Chlorhexadol</p>

<p class=MsoNormal style='line-height:150%'>     (3)   Glutethimide</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Lysergic acid</p>

<p class=MsoNormal style='line-height:150%'>     (5)   Lysergic acid amide</p>

<p class=MsoNormal style='line-height:150%'>     (6)   Methyprylon</p>

<p class=MsoNormal style='line-height:150%'>     (7)   Phencyclidine</p>

<p class=MsoNormal style='line-height:150%'>     (8)   Sulfondiethylmethane</p>

<p class=MsoNormal style='line-height:150%'>     (9)   Sulfonethylmethane</p>

<p class=MsoNormal style='line-height:150%'>     (10) Sulfonmethane</p>

<p class=MsoNormal style='line-height:150%'>     (11) Ketamine hydrochloride</p>

<p class=MsoNormal style='line-height:150%'>     <u>(12) Except when acquired,
prescribed, administered, or dispensed by a veterinarian in the course of the
professional practice of veterinary medicine, any of the following substances,
including their salts, isomers, and salts of isomers whenever the existence of
such salts, isomers, or salts of isomers is possible with the specific chemical
designation:  xylazine; xylazine-M (2,6Mich dimethylaniline); xylazine-M
(N-thiourea-2,6-dimethylaniline); xylazine-M (sulfone-HO-) isomer 2; xylazine-M
(HO-2,6-dimethylaniline isomer 1); xylazine-M (HO-2,6-dimethylaniline isomer
2); xylazine-M (oxo-); xylazine-M (HO-) isomer 1; xylazine-M (HO-) isomer1
glucuronide; xylazine-M (HO-) isomer 2; xylazine-M (HO-) isomer 2 glucuronide;
xylazine-M (HO-oxo-) isomer 1; xylazine-M (HO-oxo-) isomer 1 glucuronide;
xylazine-M (HO-oxo-) isomer 2; xylazine-M (HO-oxo-) isomer 2 glucuronide;
xylazine-M (sulfone); xylazine-M (sulfone-HO-) isomer 1; and any compound,
mixture, or preparation that contains any quantity of any of the substances
listed in this paragraph</u>.</p>

<p class=MsoNormal style='line-height:150%'>     e.     Nalorphine.</p>

<p class=MsoNormal style='line-height:150%'>     f.     Any material, compound,
mixture, or preparation containing limited quantities of any of the following
narcotic drugs, or any salts thereof:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   Not more than 1.80 grams
of codeine or any of its salts per 100 milliliters or not more than 90 milligrams
per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
of opium.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   Not more than 1.80 grams
of codeine or any of its salts per 100 milliliters or not more than 90
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts.</p>

<p class=MsoNormal style='line-height:150%'>     (3)   Not more than 300
milligrams of dihydrocodeinone or any of its salts per 100 milliliters or not
more than 15 milligrams per dosage unit, with a four-fold or greater quantity
of an isoquinoline alkaloid of opium.</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Not more than 300
milligrams of dihydrocodeinone or any of its salts per 100 milliliters or not
more than 15 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts.</p>

<p class=MsoNormal style='line-height:150%'>     (5)   Not more than 1.80 grams
of dihydrocodeine or any of its salts per 100 milliliters or not more than 90
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts.</p>

<p class=MsoNormal style='line-height:150%'>     (6)   Not more than 300
milligrams of ethylmorphine or any of its salts per 100 milliliters or not more
than 15 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts.</p>

<p class=MsoNormal style='line-height:150%'>     (7)   Not more than 500
milligrams of opium or any of its salts per 100 milliliters or per 100 grams,
or not more than 25 milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts.</p>

<p class=MsoNormal style='line-height:150%'>     (8)   Not more than 50
milligrams of morphine or any of its salts per 100 milliliters or per 100 grams
with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts.</p>

<p class=MsoNormal style='line-height:150%'>     g.    The director may by
regulation except any compound, mixture, or preparation containing any
stimulant or depressant substance listed in subsections c. and d. of this
schedule from the application of all or any part of this act if the compound,
mixture, or preparation contains one or more active medicinal ingredients not
having a stimulant or depressant effect on the central nervous system;
provided, that such admixtures shall be included therein in such combinations,
quantity, proportion, or concentration as to vitiate the potential for abuse of
the substances which do have a stimulant or depressant effect on the central
nervous system.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2007, c.244, s.5)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    (New section) The
Director of the Division of Consumer Affairs in the Department of Law and
Public Safety shall promulgate rules and regulations, pursuant to the
Administrative Procedure Act, P.L.1968, c.410 (C.52:14B-1 et seq.), to
implement the provisions of this act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    This act shall take
effect immediately.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill classifies xylazine
as a Schedule III controlled dangerous substance (CDS), except when it is
acquired, prescribed, administered, or dispensed by a veterinarian in the
course of the professional practice of veterinary medicine.</p>

<p class=MsoNormal style='line-height:150%'>     Drugs listed as Schedule III
CDS that do not otherwise carry a specific criminal penalty are subject to
certain standard criminal penalties related to the illegal manufacturing,
distribution, dispensing, possession, and use of the drug.  </p>

<p class=MsoNormal style='line-height:150%'>     Accordingly, a person
convicted of the illegal manufacture, distribution, dispensing, possession,
use, or being under the influence of xylazine would be guilty of a crime of the
third degree, which is punishable by imprisonment for three to five years, as
well as a fine of up to $25,000 in the case of manufacturing, distribution, and
dispensing offenses, and a fine of up to $35,000 for possession, use, or
intoxication offenses.  Certain enhanced penalties would apply for offenses
committed within 1,000 feet of school property, for offenses committed within
500 feet of certain public spaces, and for distributing xylaxine to a person
under 18 years of age or who is pregnant.</p>

<p class=MsoNormal style='line-height:150%'>     Xylazine, which is also known
by the street names tranq, tranq dope, and zombie drug, has been approved
for use as an animal sedative and is commonly used in veterinary practice, but
has not been approved for use in humans.  However, it has been reported that
xylazine has been increasingly detected in illegal street drugs, and
particularly in opioid drugs, as it can enhance and prolong the euphoric
effects of opioids.  However, xylazine is not itself an opioid, and it does not
respond to opioid antidotes like naloxone.  Accordingly, a person who consumes
an opioid drug that includes xylazine may die of an overdose notwithstanding
the prompt administration of an opioid antidote.  Furthermore, xylazine is
highly addictive, results in severe withdrawal symptoms, and can cause severe
skin ulcers and abscesses.  Although some drug users seek out xylazine for its
effects in enhancing opioid intoxication, others may not be aware they are
consuming it or that they are at enhanced risk of overdose and other
drug-related injuries.</p>

<p class=MsoNormal style='line-height:150%'>     It is the sponsors belief
that listing xylazine as a Schedule III CDS, except when it is being used in
the course of practicing veterinary medicine, will help protect the lives of
New Jersey citizens and prevent unnecessary deaths.</p>

</div>

</body>

</html>
